Results 171 to 180 of about 8,676,945 (352)

The Value of Transportation for Improving the Quality of Life of the Rural Elderly [PDF]

When an elderly individual living in a rural community is no longer able to drive, issues that come with living in an isolated area (i.e. limited access to health and personal services, distance between home and town centers) are exaggerated and the ...
Chen, Junyi, Cherrington, Linda, Dudensing, Rebekka M., Israel, Alicia, Jin, Yanhong H., Mjelde, James W.   +5 more
core   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

The value of life in English law: revered but not sacred? [PDF]

Leg Stud (Soc Leg Scholars), 2016
Heywood R, Mullock A.
europepmc   +1 more source

Development and Shelf-life Evaluation of Value Added Edible Products from Bamboo Shoots [PDF]

, 2012
A. K. Pandey, Vijayalakshmi Ojha, Sanchita Choubey   +2 more
openalex   +1 more source

Value addition of tilapia (Oreochromis niloticus): Preparation of fillet and shelf-life assessment

, 2021
Mukta Sarker, Md. Mehedy Hasan, Umme Hani, Md Foysal Ahmad, Md. Abu Sayeed, Mohammad Abu Jafor Bapary, Tofael Ahmed Sumon, Md. Ashraf Hussain   +7 more
openalex   +2 more sources

Eliciting a value set for the Swedish Capability-Adjusted Life Years instrument (CALY-SWE) [PDF]

, 2023
Kaspar Walter Meili, Brendan Mulhern, Richard Ssegonja, Fredrik Norström, Inna Feldman, Anna Månsdotter, Jan Hjelte, Lars Lindholm   +7 more
openalex   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

A Deliberative Approach to Valuing Capabilities: Assessing and Valuing Changes in the Well-Being of those Close to Patients Receiving Supportive End of Life Care

, 2021
Philip Kinghorn, Alastair Canaway, Cara Bailey, Hareth Al‐Janabi, Joanna Coast   +4 more
openalex   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Is "end of life" a special case? Connecting Q with survey methods to measure societal support for views on the value of life-extending treatments. [PDF]

Health Econ, 2018
Mason H, Collins M, McHugh N, Godwin J, Van Exel J, Donaldson C, Baker R.   +6 more
europepmc   +1 more source